Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

652 - Neuroendocrine neoplasms of the esophagus - emerging clinicopathological trends and outcomes of a rare entity


19 Dec 2015


Poster presentation 1


Mangesh Kamath


Annals of Oncology (2015) 26 (suppl_9): 40-41. 10.1093/annonc/mdv522


M.P. Kamath1, L. D1, K. Lakshmaiah1, L.A. Jacob1, R.V. Kumar2, S. Babu1, G. Babu1, A.S. Komaranchath1, A. S1

Author affiliations

  • 1 Medical Oncology, Kidwai Memorial Institute of Oncology, 560030 - Bangalore/IN
  • 2 Pathology, Kidwai Memorial Institute of Oncology, 560030 - Bangalore/IN


Abstract 652


Neuroendocrine neoplasms (NENs) of the esophagus are very uncommon with only a few studies published worldwide. Studies on clinical profile, management and outcomes are very uncommon. The aim was to study the clinicopathological characteristics and outcomes of neuroendocrine neoplasms of the esophagus.


We report the largest single institution retrospective review of 43 patients of esophageal NENs out of our registry of gastrointestinal neuroendocrine tumors treated between 2005 and 2014. Data on the incidence, tumor location, clinical symptoms, stage at presentation, grading, treatment protocol and treatment outcomes was collected and analyzed.


Among 124 NENs arising in different gastrointestinal sites, esophageal NENs were found in 43 cases. The mean patient age was 55.8 years. The male: female ratio was 1.5:1. 81.4 % of the tumors were located in the lower third of the esophagus and gastro-esophageal junction. Neuroendocrine carcinomas (NEC; G3) accounted for the vast majority of NENs (83.7%). 53.5 % patients were Stage IV and 32.5 % were Stage III at presentation. The combined median survival of Stages II and III patients was 18.25 months, with treatment. The median survival of treated patients with metastatic disease was 6.5 months.


Esophageal NENs most commonly were neuroendocrine carcinomas, presented in metastatic stage and were associated with poor prognosis. Grade 1 (G1) and Grade 2 (G2) had better outcome than NEC (G3). In non-metastatic disease, presence of lymph node metastasis and unresectable disease had poorer outcomes.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings